Please assess the completion status of the following clinical trial:

Trial Title: IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females 18-45 years of age~* Confirmed type 1 VWD, as defined by low VWF:RCoF or low VWF:Ag and qualitatively normal VWF multimers~* Menorrhagia refractory to estrogens, hormones, hemostatic agents~* Willingness to have blood drawn~Exclusion Criteria:~* Use of immunomodulatory or experimental drugs, or diuretics~* Pregnant or lactating women or those unwilling to use contraception during study~* Previous cardiac disease, congestive failure, arrhythmia (e.g., atrial fibrillation, atrial flutter), hypertension, MI, stroke, or thrombosis~* Past allergic reaction to Neumega or DDAVP~* Surgery within the past 8 weeks~* Inability to comply with study protocol requirements~* Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs~* Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing substantial quantities of FVIII and/or VWF within five days of study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Oprelvekin, Interleukin 11, IL-11 (Type: EXPERIMENTAL): 25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).